Josh Echols
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Josh Echols has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Amna Siddiqui
Department of Biochemistry & Molecular Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Aneta Kaczmarczyk
Department of Biochemistry & Molecular Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Chuanxi Richard Sun
Department of Biochemistry & Molecular Genetics, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Corinne Elizabeth Augelli-Szafran
Preclinical Operations, Southern Research, 2000 Ninth Avenue South, Birmingham, AL, USA
1 shared publication - David M. Bedwell
Departments of Biochemistry & Molecular Genetics, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL 35294, USA
1 shared publication - Halil Dündar
A Department of Biotechnology , Middle East Technical University , Ankara , Turkey
1 shared publication
Latest Publications
- Open Access
- 24 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4521
Triamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome)
Mucopolysaccharidosis I-Hurler (MPS I-H) is caused by the loss of α-L-iduronidase, a lysosomal enzyme that degrades glycosaminoglycans. Current therapies cannot treat many MPS I-H manifestations. In this study, triamterene, an FDA-approved, antihypertensive diuretic, was found to suppress translation termination at a nonsense mutation associated with MPS I-H. Triamterene rescued enough α-L-iduronidase function to normalize glycosaminoglycan storage in cell and animal models. This new function of triamterene operates through premature termination codon (PTC) dependent mechanisms that are unaffected by epithelial sodium channel activity, the target of triamterene’s diuretic function. Triamterene represents a potential non-invasive treatment for MPS I-H patients carrying a PTC.
- 24 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (5) , 4521
Open AccessTriamterene Functions as an Effective Nonsense Suppression Agent for MPS I-H (Hurler Syndrome)
Mucopolysaccharidosis I-Hurler (MPS I-H) is caused by the loss of α-L-iduronidase, a lysosomal enzyme that degrades glycosaminoglycans. Current therapies cannot treat many MPS I-H manifestations. In this study, triamterene, an FDA-approved, antihypertensive diuretic, was found to suppress translation termination at a nonsense mutation associated with MPS I-H. Triamterene rescued enough α-L-iduronidase function to normalize glycosaminoglycan storage in cell and animal models. This new function of triamterene operates through premature termination codon (PTC) dependent mechanisms that are unaffected by epithelial sodium channel activity, the target of triamterene’s diuretic function. Triamterene represents a potential non-invasive treatment for MPS I-H patients carrying a PTC.